Facebook
X
LinkedIn
ForwardMayo Clinic Hepato-Pancreatico-Biliary Cancer Symposium 2026 - Livestream (virtual)
November 13 - 14, 2026 - Internet Live-Activity - Las Vegas, Nevada
Broadcast in Pacific Time
Course Directors - Tanios S. Bekaii-Saab, M.D., Mitesh J. Borad, M.D., G. Dan Duda, D.M.D., Ph.D and Mark J. Truty, M.D., M.S.
The 2026 Mayo Clinic Hepato-Pancreatico-Biliary Cancer Symposium will review multidisciplinary, stage-specific management of hepatobiliary and pancreatic cancers. It highlights advances in immunotherapy, targeted and biomarker-driven treatments, surgical and transplant strategies, and emerging technologies such as AI and liquid biopsy to optimize patient outcomes.
Target Audience
This course is intended for surgeons, gastroenterologists, medical and radiation oncologists, laboratory scientists, and allied health professionals in the following specialties: medical oncology, hematology, gastroenterology, radiation oncology, surgical oncology, pathology, radiology, and laboratory research science.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Evaluate current first-line and evolving systemic treatment strategies for advanced hepatocellular carcinoma (HCC), including anti-angiogenic/immunotherapy combinations, STRIDE, and dual checkpoint inhibition approaches.
- Apply stage-specific, multidisciplinary treatment strategies for hepatocellular carcinoma and cholangiocarcinoma, incorporating surgical, locoregional, and transplant-based approaches.
- Integrate precision oncology into hepatobiliary and pancreatic cancers by utilizing biomarkers (e.g., HER2, IDH1/2, FGFR) and liquid biopsy technologies to guide targeted therapy selection.
- Assess optimal management strategies for pancreatic adenocarcinoma across disease stages, including neoadjuvant/adjuvant sequencing, resectability criteria, and emerging RAS-targeted therapies.
- Develop evidence-based treatment plans for rare hepatic and pancreatic tumors, including fibrolamellar HCC, pancreatic neuroendocrine tumors (PNETs), and uncommon exocrine pancreatic malignancies.
- Analyze emerging technologies and population health strategies, including artificial intelligence for early cancer detection and national approaches to addressing biliary tract cancer burden.
Attendance at any Mayo Clinic course does not indicate or guarantee competence or proficiency in the skills, knowledge or performance of any care or procedure(s) which may be discussed or taught in this course.
Broadcast in Pacific Time
All travel and lodging expenses are the sole responsibility of the individual registrant.
Accreditation Statement
In support of improving patient care, Mayo Clinic College of Medicine and Science is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Credit Statement(s):
AMA
Mayo Clinic College of Medicine and Science designates this live activity for a maximum of 11.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAPA
Mayo Clinic College of Medicine and Science has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 11.50 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
ANCC
Mayo Clinic College of Medicine and Science designates this activity for a maximum of 11.50 ANCC contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Other Healthcare Professionals:
A record of attendance will be provided to all registrants for requesting credits in accordance with state nursing boards, specialty societies or other professional associations.
For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to review disclosures.
Available Credit
- 11.50 AAPA Category 1
- 11.50 AMA PRA Category 1 Credit™
- 11.50 ANCC
- 11.50 Attendance
Thank you for your interest in Hepato-Pancreatico-Biliary Cancer Symposium 2026. This course is currently in the early planning stages. If you’d like to be notified when opportunities become available, please add your name to our Notify Me list. Signing up to be notified will ensure that you receive an email when exhibitor information is available. No additional information is available until then.
Price
Broadcast in Pacific Time
Before registering, please update your profile.
To claim credit for livestream participation in this course, learners must view the content during the hours posted for the live activity. This course is not approved for on-demand delivery.
Commitment to Belonging and Inclusion
Mayo Clinic School of Continuous Professional Development (MCSCPD) strives to foster a learning environment in which all individuals are valued, allowing all to achieve their fullest potential.
Every effort will be made to accommodate dietary requirements; however, some requests may not be feasible based on venue kitchen capabilities. Attendees will be contacted in advance if a dietary restriction cannot be fulfilled.
The Mayo Clinic School of Continuous Professional Development strives for fully accessible learning experiences. If you anticipate any barriers while attending this course, please reach out to the course coordinator who will be in touch with all registrants. If you need disability-related accommodations, please contact the Office of Wellness and Academic Support – Disability Access Services at MCCMS.DS@mayo.edu.
Cancellation and Refund Policy
View Cancellation and Refund Policy
All requests must be submitted in writing using the Contact Us Form.
Any use of this site constitutes your agreement to the Terms and Conditions of Registration.